1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Impedimed Limited

Impedimed Limited

0.00
AUD
0.00
(0.00%)
-0.01EPS
18.30MMarket Cap
Feb 25Next Earn
Impedimed Limited
ASX:IPD
(Australian Securities Exchange)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
0.02
0.02
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
0.01
0.01
Revenue per Share
-0.09
-0.07
-0.04
-0.04
-0.05
-0.08
-0.07
-0.07
-0.06
-0.04
-0.02
-0.01
-0.01
-0.01
-0.01
-0.01
Basic EPS, GAAP
-0.07
-0.07
-0.04
-0.03
-0.04
-0.07
-0.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.12
0.09
0.05
0.05
0.11
0.22
0.15
0.09
0.04
0.03
0.02
0.03
0.03
0.02
0.01
- -
Book Value per Share
0.11
0.08
0.04
0.05
0.11
0.21
0.14
0.08
0.03
0.02
0.01
0.02
0.02
0.01
- -
- -
Tangible Book Value per Share
158
173
195
211
281
335
393
395
397
595
1,202
1,679
1,800
2,022
2,019
2,134
Basic Weighted Avg Shares
4
3
3
4
5
6
6
5
4
6
8
10
11
10
13
15
Sales/Revenue/Turnover
-392.44
-457.22
-347.75
-227.26
-312.65
-452.06
-533.33
-638.71
-659.15
-448.84
-276.22
-205.21
-204.4
-241.76
-190.44
-153.69
Operating Margin (%)
1
1
- -
- -
- -
- -
- -
- -
1
1
2
3
3
2
5
4
Depreciation Expense
-15
-12
-8
-8
-15
-26
-28
-27
-24
-21
-21
-20
-21
-20
-23
-25
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-381.32
-419.08
-309.7
-225.36
-305.47
-448.63
-478.17
-566.48
-588.65
-375.43
-247.89
-189.37
-182.43
-196.86
-182.62
-170.44
Profit Margin (%)
18
15
8
11
32
82
56
32
10
20
18
39
46
25
22
17
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
1
14
16
LT Debt
21
17
11
14
35
85
59
36
16
27
26
51
61
41
20
10
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-69.08
-64.97
-60.67
-65.78
-61.18
-43.27
-38.28
-57.33
-93.16
-99.09
-78.32
-51.92
-36.67
-38.95
-75.89
-162.35
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-7.31%
-2.75%
-50.3%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-0.08%
4.06%
7.19%
Sales/Revenue/Turnover
11.74%
12.72%
14.85%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10
2025
- -
- -
13
2026
- -
- -
15

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ImpediMed Limited ImpediMed Limited is an Australian Stock Exchange-listed medical technology company that designs and manufactures devices employing bioimpedance spectroscopy (BIS) technology for the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients; its core products include the SOZO Digital Health Platform, which provides comprehensive body composition analysis, fluid status monitoring, and L-Dex analysis for early detection of lymphedema, particularly breast cancer-related lymphedema (BCRL), as well as specialized devices for lymphedema screening and management in oncology, heart failure, and hydration assessment settings. The company targets healthcare professionals in breast cancer centers, hospitals, and clinics, serving patients undergoing cancer treatment, surgical procedures, and chronic condition management; it operates globally with headquarters in Brisbane, Australia, and additional offices in the United States (Carlsbad, California, and Bloomington, Minnesota) and Europe. Founded in 1999, ImpediMed Limited drives innovation focused on secondary lymphedema challenges, with its SOZO platform recognized in updated 2024 National Accreditation Program for Breast Centers (NAPBC) standards as an evidence-based tool for lymphedema prevention. In February 2025, the company secured a five-year $15 million growth capital facility from SWK Holdings Corporation SWK Holdings Corporation, providing non-dilutive funding flexibility to accelerate commercialization of the SOZO platform and expand market adoption amid increasing U.S. payer coverage for over 258 million lives; this strategic financing, advised by Armentum Partners, supports ongoing execution of its growth strategy without dilution to shareholders.

Company News

Company News APIChatGPT

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Q4 2026 Earnings Call Transcript

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Shareholder/Analyst Call Prepared Remarks Transcript

  • defenseworld.net

    ImpediMed Q2 Earnings Call Highlights

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript